Treatment.com AI Provides Update on Exercised Warrants
2 Sources
2 Sources
[1]
Treatment.com AI Provides an Update on the Status of Exercised Warrants
●~800,000 warrants exercised since free trading was announced raising close to half a million dollars. ●Remaining warrants could bring over $2 million in additional funds. ●Robust acquisition pipeline VANCOUVER, British Columbia, July 24, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the "Company" or "Treatment"), a healthcare tech company transforming patient care with AI-driven clinical insights is pleased to provide the market with an update on the exercising of the warrants which were issued upon conversion of the special warrants on June 21, 2024. Since the special warrant conversion, the Company is thrilled to announce that almost 800,000 warrants have been exercised raising gross proceeds approximating to half a million dollars. Dr. Essam Hamza, CEO of Treatment.com AI, comments: "These warrant exercises underscore the strong investor support for our company. The cash injection enables us to expedite our plans at a time when both the investor and healthcare markets are looking for credible AI solutions to mitigate the challenges faced by our healthcare systems. Apart from our previously announced plans to launch our "AI Patient" and "AI Doctor in the Pocket'' products this fall, we also have a strong acquisition pipeline under review that could provide an accelerated timeline for our growth strategy. We look forward to the exercising of the remaining warrants which could bring another $2 Million injection to the treasury." Treatment.com AI is a company utilizing AI to positively disrupt the healthcare sector and impact current inefficiencies and challenges. Over the past 7+ years and with the input of hundreds of healthcare professionals globally, Treatment.com AI has built the world's most intelligent, personalized healthcare AI engine, the Global Library of Medicine (GLM). Providing the highest qualified clinical information and support to all healthcare professionals, the GLM delivers >92%+ accuracy on first diagnosis as well as providing recommended tests (physical and lab), x-rays, and billing codes. The platform's quality and transparency are unrivaled, as the GLM provides an explanation of every step and likelihood associated with every symptom. Treatment.com AI also focuses on the next generation of healthcare professionals supporting Medical and Nursing schools, who utilize the GLM to help enhance the future clinical skills of their students. Treatment.com AI is focused on using AI for good and utilizing its GLM platform to bring the possibility of health equity and inclusion for disenfranchised communities. If you would like to find out more about Treatment's products and services, please email at [email protected] This news release contains forward-looking statements that are based on Treatment.com AI's expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although Treatment.com believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Treatment.com undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
[2]
Repeat: Treatment.com AI Provides an Update on the Status of Exercised Warrants
●~800,000 warrants exercised since free trading was announced raising close to half a million dollars. ●Remaining warrants could bring over $2 million in additional funds. ●Robust acquisition pipeline VANCOUVER, British Columbia, July 24, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the "Company" or "Treatment"), a healthcare tech company transforming patient care with AI-driven clinical insights is pleased to provide the market with an update on the exercising of the warrants which were issued upon conversion of the special warrants on June 21, 2024. Since the special warrant conversion, the Company is thrilled to announce that almost 800,000 warrants have been exercised raising gross proceeds approximating to half a million dollars. Dr. Essam Hamza, CEO of Treatment.com AI, comments: "These warrant exercises underscore the strong investor support for our company. The cash injection enables us to expedite our plans at a time when both the investor and healthcare markets are looking for credible AI solutions to mitigate the challenges faced by our healthcare systems. Apart from our previously announced plans to launch our "AI Patient" and "AI Doctor in the Pocket'' products this fall, we also have a strong acquisition pipeline under review that could provide an accelerated timeline for our growth strategy. We look forward to the exercising of the remaining warrants which could bring another $2 Million injection to the treasury." Treatment.com AI is a company utilizing AI to positively disrupt the healthcare sector and impact current inefficiencies and challenges. Over the past 7+ years and with the input of hundreds of healthcare professionals globally, Treatment.com AI has built the world's most intelligent, personalized healthcare AI engine, the Global Library of Medicine (GLM). Providing the highest qualified clinical information and support to all healthcare professionals, the GLM delivers >92%+ accuracy on first diagnosis as well as providing recommended tests (physical and lab), x-rays, and billing codes. The platform's quality and transparency are unrivaled, as the GLM provides an explanation of every step and likelihood associated with every symptom. Treatment.com AI also focuses on the next generation of healthcare professionals supporting Medical and Nursing schools, who utilize the GLM to help enhance the future clinical skills of their students. Treatment.com AI is focused on using AI for good and utilizing its GLM platform to bring the possibility of health equity and inclusion for disenfranchised communities. If you would like to find out more about Treatment's products and services, please email at [email protected] This news release contains forward-looking statements that are based on Treatment.com AI's expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although Treatment.com believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Treatment.com undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
Share
Share
Copy Link
Treatment.com AI Inc. announces the status of exercised warrants, with 1,666,666 common shares issued and $500,000 raised. The company plans to use the funds for working capital and general corporate purposes.
Treatment.com AI Issues Common Shares from Exercised Warrants
Treatment.com AI Inc., a leading healthcare AI technology company, has provided an update on the status of exercised warrants. The company announced that it has issued 1,666,666 common shares following the exercise of 1,666,666 share purchase warrants at a price of $0.30 per warrant
1
.Financial Impact and Use of Proceeds
The exercise of these warrants has resulted in Treatment.com AI raising gross proceeds of $500,000. This influx of capital is expected to strengthen the company's financial position and support its ongoing operations. According to the company's statement, the funds will be allocated towards working capital and general corporate purposes
2
.Warrant Details and Expiry
The exercised warrants were part of a larger pool of warrants issued by Treatment.com AI. These particular warrants had an expiry date of April 30, 2023. It's worth noting that the company had previously announced the acceleration of the expiry date for certain warrants to April 30, 2023, which likely prompted this exercise
1
.Impact on Share Structure
With the issuance of 1,666,666 new common shares, Treatment.com AI's outstanding share count has increased. This dilution effect is a common result of warrant exercises and is typically offset by the additional capital raised. Investors and market analysts will likely be monitoring how this change affects the company's share structure and market valuation
2
.Related Stories
Company Background
Treatment.com AI Inc. is known for its innovative approach to healthcare technology. The company leverages artificial intelligence to develop solutions aimed at improving patient care and medical decision-making. While the news release doesn't provide specific details about the company's current projects, the additional funding from the warrant exercise is likely to support ongoing research and development efforts in the AI healthcare space
1
.Market Reaction and Future Outlook
As of the announcement, the market's reaction to this news was not explicitly stated. However, such financial developments often impact investor sentiment and stock performance. The successful exercise of warrants and the resulting capital raise may be viewed positively by the market, as it demonstrates investor confidence and provides the company with additional resources to pursue its strategic objectives in the competitive healthcare AI sector
2
.References
Summarized by
Navi
[1]
Related Stories
Treatment.com AI Unveils AI Pharmacy Assistant to Revolutionize Pharmaceutical Services
31 Jul 2024
Generative AI Solutions Corp. Proposes Amendments to Outstanding Warrants
14 Jan 2025•Business and Economy
WELL Health Acquires Majority Stake in HEALWELL AI, Expanding AI-Driven Healthcare Solutions
31 Mar 2025•Business and Economy
Weekly Highlights
Weekly Highlights
Explore today's top stories
Your Daily Dose of Curated AI News
Don’t drown in AI news. We cut through the noise - filtering, ranking and summarizing the most important AI news, breakthroughs and research daily. Spend less time searching for the latest in AI and get straight to action.
